NorthStrive Biosciences (NASDAQ:ELAB) has launched Phase III of its AI Development Program in collaboration with Yuva Biosciences, aiming to validate small-molecule candidates for muscle preservation through mitochondrial function enhancement.
The initiative, which focuses on AI-prioritized compounds, seeks to accelerate drug discovery by leveraging biological data and advanced mitochondrial biogenesis insights.
Phase III will focus on generating key biological data, including cytotoxicity screening and ANT1 expression testing at various timepoints.
The program will utilize YuvaBio’s MitoNova™ AI classifier, which analyzes a vast mitochondrial biogenesis dataset to prioritize the most promising candidates for further validation.
This strategic approach is designed to streamline the discovery process and reduce the number of compounds advanced to later development stages.
The Phase III trial is expected to take approximately 6 to 9 weeks to complete, providing critical data to inform the next steps in NorthStrive’s ongoing efforts to identify effective treatments for muscle preservation.